

Recce to present at two investor conferences

SYDNEY, Australia, 25 January 2018: Recce Pharmaceuticals Ltd (ASX: RCE), the company developing a new class of synthetic antibiotics, today announced Executive Director James Graham will present at the Proactive Investor conferences in Melbourne on Wednesday 31 January and Sydney on Thursday 1 February.

Mr Graham will provide an overview of the company, including pending milestones and recent progress towards commercialising its new antibiotic therapies for tackling superbugs.

Investors are invited to attend by registering their interest before Monday 29 January 2018 by calling (02) 9280 0700 or online at <http://www.proactiveinvestors.com.au/events>

Melbourne – Wednesday, 31 January 2018 from 12:00pm to 2:00pm
CQ Melbourne, Events Room 1 (113 Queen Street, Melbourne)

Sydney – Thursday, 1 February 2018 from 12:00pm to 2:00pm
Radisson Blu Hotel, Marble Room (Cnr. Pitt and O'Connell Street, Sydney)

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a [new class of synthetic antibiotics with broad spectrum activity](#) designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results to date. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-man clinical trials.



ASX: RCE

Head Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

R&D Centre – Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA